NCM·Healthcare·$173M·#290 / 520 in Healthcare
PRQR ProQR Therapeutics N.V.
40HIGH RISK
CATEGORY BREAKDOWN
GROWTH0
QUALITY0
STABILITY74
VALUATION43
GOVERNANCE87
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
-15.9%
0
> 50% strong
Gross Margin
Revenue retained after direct costs
N/A
0
> 50% strong
Cash Runway
Months of cash at current burn rate
21 months
75
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
32.3%
73
< 25% strong
Price / Sales
Market cap relative to trailing revenue
10.6x
43
< 3x strong
Rule of 40
Growth rate plus operating margin
-289
0
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
17.7%
80
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
-2.2%
100
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE PRQR WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when PRQR's score changes by 5+ points.
DATA INFO
Last updated: May 4, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.